vs
CapsoVision, Inc（CV）与TransMedics Group, Inc.（TMDX）财务数据对比。点击上方公司名可切换其他公司
TransMedics Group, Inc.的季度营收约是CapsoVision, Inc的45.4倍（$160.8M vs $3.5M）。TransMedics Group, Inc.净利率更高（65.6% vs -223.9%，领先289.4%）。TransMedics Group, Inc.自由现金流更多（$19.0M vs $-5.7M）
CapsoVision, Inc.是一家医疗科技企业，专注研发、生产先进胶囊内窥镜系统及配套诊断解决方案，旗下非侵入式胃肠道成像产品供应全球多地的医院、消化科诊所及医疗专业人员，助力提升消化道疾病检测准确率与患者诊疗体验。
TransMedics Group, Inc.是一家专注于器官移植领域的医疗科技企业，核心产品器官护理系统可在运输过程中维持捐献器官的活性，提升心、肺、肝、肾移植手术的成功率，服务覆盖北美、欧洲及亚太地区的移植中心与器官获取组织。
CV vs TMDX — 直观对比
营收规模更大
TMDX
是对方的45.4倍
$3.5M
净利率更高
TMDX
高出289.4%
-223.9%
自由现金流更多
TMDX
多$24.7M
$-5.7M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $3.5M | $160.8M |
| 净利润 | $-7.9M | $105.4M |
| 毛利率 | 54.1% | 58.1% |
| 营业利润率 | -226.7% | 13.2% |
| 净利率 | -223.9% | 65.6% |
| 营收同比 | — | 32.2% |
| 净利润同比 | — | 1436.9% |
| 每股收益（稀释后） | $-0.17 | $2.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVTMDX
| Q4 25 | — | $160.8M | ||
| Q3 25 | $3.5M | $143.8M | ||
| Q2 25 | $3.3M | $157.4M | ||
| Q1 25 | — | $143.5M | ||
| Q4 24 | — | $121.6M | ||
| Q3 24 | — | $108.8M | ||
| Q2 24 | — | $114.3M | ||
| Q1 24 | — | $96.8M |
净利润CVTMDX
| Q4 25 | — | $105.4M | ||
| Q3 25 | $-7.9M | $24.3M | ||
| Q2 25 | $-4.6M | $34.9M | ||
| Q1 25 | — | $25.7M | ||
| Q4 24 | — | $6.9M | ||
| Q3 24 | — | $4.2M | ||
| Q2 24 | — | $12.2M | ||
| Q1 24 | — | $12.2M |
毛利率CVTMDX
| Q4 25 | — | 58.1% | ||
| Q3 25 | 54.1% | 58.8% | ||
| Q2 25 | 54.6% | 61.4% | ||
| Q1 25 | — | 61.5% | ||
| Q4 24 | — | 59.2% | ||
| Q3 24 | — | 55.9% | ||
| Q2 24 | — | 60.6% | ||
| Q1 24 | — | 61.9% |
营业利润率CVTMDX
| Q4 25 | — | 13.2% | ||
| Q3 25 | -226.7% | 16.2% | ||
| Q2 25 | -140.3% | 23.2% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 7.1% | ||
| Q3 24 | — | 3.6% | ||
| Q2 24 | — | 10.9% | ||
| Q1 24 | — | 12.8% |
净利率CVTMDX
| Q4 25 | — | 65.6% | ||
| Q3 25 | -223.9% | 16.9% | ||
| Q2 25 | -139.5% | 22.2% | ||
| Q1 25 | — | 17.9% | ||
| Q4 24 | — | 5.6% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 10.7% | ||
| Q1 24 | — | 12.6% |
每股收益（稀释后）CVTMDX
| Q4 25 | — | $2.59 | ||
| Q3 25 | $-0.17 | $0.66 | ||
| Q2 25 | $-2.02 | $0.92 | ||
| Q1 25 | — | $0.70 | ||
| Q4 24 | — | $0.19 | ||
| Q3 24 | — | $0.12 | ||
| Q2 24 | — | $0.35 | ||
| Q1 24 | — | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $20.4M | $473.1M |
| 总资产 | $25.7M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CVTMDX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $330.1M | ||
| Q2 24 | — | $362.8M | ||
| Q1 24 | — | $350.2M |
股东权益CVTMDX
| Q4 25 | — | $473.1M | ||
| Q3 25 | $20.4M | $355.2M | ||
| Q2 25 | $-139.0M | $318.1M | ||
| Q1 25 | — | $266.3M | ||
| Q4 24 | — | $228.6M | ||
| Q3 24 | — | $209.9M | ||
| Q2 24 | — | $189.9M | ||
| Q1 24 | — | $159.5M |
总资产CVTMDX
| Q4 25 | — | $1.1B | ||
| Q3 25 | $25.7M | $946.0M | ||
| Q2 25 | $9.5M | $890.5M | ||
| Q1 25 | — | $837.5M | ||
| Q4 24 | — | $804.1M | ||
| Q3 24 | — | $785.6M | ||
| Q2 24 | — | $758.6M | ||
| Q1 24 | — | $723.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.7M | $34.5M |
| 自由现金流经营现金流 - 资本支出 | $-5.7M | $19.0M |
| 自由现金流率自由现金流/营收 | -160.5% | 11.8% |
| 资本支出强度资本支出/营收 | 0.3% | 9.7% |
| 现金转化率经营现金流/净利润 | — | 0.33× |
| 过去12个月自由现金流最近4个季度 | — | $133.6M |
8季度趋势，按日历期对齐
经营现金流CVTMDX
| Q4 25 | — | $34.5M | ||
| Q3 25 | $-5.7M | $69.6M | ||
| Q2 25 | $-9.5M | $91.6M | ||
| Q1 25 | — | $-2.9M | ||
| Q4 24 | — | $19.7M | ||
| Q3 24 | — | $6.9M | ||
| Q2 24 | — | $25.7M | ||
| Q1 24 | — | $-3.4M |
自由现金流CVTMDX
| Q4 25 | — | $19.0M | ||
| Q3 25 | $-5.7M | $61.9M | ||
| Q2 25 | $-9.6M | $82.5M | ||
| Q1 25 | — | $-29.9M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | — | $-41.3M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $-47.6M |
自由现金流率CVTMDX
| Q4 25 | — | 11.8% | ||
| Q3 25 | -160.5% | 43.1% | ||
| Q2 25 | -289.0% | 52.4% | ||
| Q1 25 | — | -20.8% | ||
| Q4 24 | — | 5.0% | ||
| Q3 24 | — | -38.0% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | -49.2% |
资本支出强度CVTMDX
| Q4 25 | — | 9.7% | ||
| Q3 25 | 0.3% | 5.3% | ||
| Q2 25 | 2.1% | 5.8% | ||
| Q1 25 | — | 18.8% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 44.3% | ||
| Q2 24 | — | 20.8% | ||
| Q1 24 | — | 45.6% |
现金转化率CVTMDX
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | 2.86× | ||
| Q2 25 | — | 2.62× | ||
| Q1 25 | — | -0.11× | ||
| Q4 24 | — | 2.87× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | — | -0.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CV
暂无分部数据
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
